REGENEREX PHARMA, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In USD, except per-share amounts

	FY2024 12 months to Mar 31, 2025	FY2023 12 months to Mar 31, 2024	FY2022 12 months to Mar 31, 2023	FY2021 12 months to Mar 31, 2022	FY2020 12 months to Mar 31, 2021
Net loss
Net loss
Loss on discontinued operations
Adjustments to reconcile net loss to cash flows used in operating activities:
Provision for write down of inventory
Depreciation and amortization
Foreign currency adjustments
Stock-based compensation
Research and development
Non-cash Research and development
Non-cash interest related to Note extension
Amortization of ROU assets, net of liabilities

Changes in operating assets and liabilities:
Inventories
Prepaid expenses
Accounts payable and accrued liabilities
Net cash used in discontinued operating activities
Accounts payable
Accrued compensation
Other accrued liabilities
Net cash used in operating activities

Website development
Computer equipment
Purchase of furniture and computer equipment
Net cash used in investing activities
Related party advances, net
Proceeds from notes payable to shareholder
Proceeds from notes payable to related parties
Other Affiliates
Affiliated Entity
Payments of notes payable to shareholders
Payments of notes payable to related parties
Proceeds from sale of common stock and warrants, net of offering costs
Net cash provided by financing activities
(Decrease) Increase in cash and equivalents
Increase (decrease) in cash and equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Accrued interest converted into note payable to shareholder
Interest
Accrued interest converted into notes payable to shareholder
Shares issued for the acquisition of intellectual property
Accrued interest converted into note payable
Accrued interest converted into notes payable to related parties
Operating lease, ROU asset and liabilities
Note payable issued for research and development
Note payable issued for Note extension

Comments